140 related articles for article (PubMed ID: 1635566)
21. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
22. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
[TBL] [Abstract][Full Text] [Related]
24. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
26. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
27. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
Cocconi G; Passalacqua R; Foladore S; Carlini P; Acito L; Maiello E; Marchi M; Gebbia V; Di Sarra S; Beretta M; Bacchi M
Melanoma Res; 2003 Feb; 13(1):73-9. PubMed ID: 12569288
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C; Thomas L; Bondarenko I; O'Day S; Weber J; Garbe C; Lebbe C; Baurain JF; Testori A; Grob JJ; Davidson N; Richards J; Maio M; Hauschild A; Miller WH; Gascon P; Lotem M; Harmankaya K; Ibrahim R; Francis S; Chen TT; Humphrey R; Hoos A; Wolchok JD
N Engl J Med; 2011 Jun; 364(26):2517-26. PubMed ID: 21639810
[TBL] [Abstract][Full Text] [Related]
29. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.
McKeage MJ; Lorentzos A; Gore ME
N Engl J Med; 1993 Jan; 328(2):140-1. PubMed ID: 8416433
[No Abstract] [Full Text] [Related]
31. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Lattanzi SC; Tosteson T; Chertoff J; Maurer LH; O'Donnell J; LeMarbre PJ; Mott L; DelPrete SA; Forcier RJ; Ernstoff MS
Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728
[TBL] [Abstract][Full Text] [Related]
32. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
Yi JH; Yi SY; Lee HR; Lee SI; Lim DH; Kim JH; Park KW; Lee J
Melanoma Res; 2011 Jun; 21(3):223-7. PubMed ID: 21471822
[TBL] [Abstract][Full Text] [Related]
33. Disseminated melanoma--is there a new standard therapy?
Guerry D; Schuchter LM
N Engl J Med; 1992 Aug; 327(8):560-1. PubMed ID: 1635572
[No Abstract] [Full Text] [Related]
34. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study.
Robinson DW; Cormier JN; Zhao N; Uhlar CM; Revicki DA; Cella D
Melanoma Res; 2012 Feb; 22(1):54-62. PubMed ID: 22027908
[TBL] [Abstract][Full Text] [Related]
35. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
36. Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma.
Chmielowska E; Potemski P; Pluzańska A
J Clin Oncol; 1995 Aug; 13(8):2146-7. PubMed ID: 7636562
[No Abstract] [Full Text] [Related]
37. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Buzaid AC; Murren JR; Durivage HJ
Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy of metastatic melanoma.
Berd D; Mastrangelo MJ
J Clin Oncol; 1995 Mar; 13(3):796-7. PubMed ID: 7884439
[No Abstract] [Full Text] [Related]
40. [Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
Kawano N; Tashiro M; Taguchi M; Kihara Y; Yoshikawa I; Syukuwa K; Yamasaki M; Kume K; Otsuki M
Nihon Shokakibyo Gakkai Zasshi; 2008 Nov; 105(11):1627-33. PubMed ID: 18987448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
